Hemab Therapeutics
Copenhagen, Denmark · Biotechnology, Health Care, Therapeutics · 90 employees
Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance
Funding history
- Funding Round — $346.7M — Jun 2026
- Series series c — $157.0M — Oct 2025
Recent signals
- Jun 01, 2026: Raised $346.7M
- Oct 27, 2025: Raised $157.0M in Series series c
- Sep 02, 2025: Hemab Appoints Anant Murthy as Chief Operating Officer
See plans & pricing → Track Hemab Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.